These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

223 related items for PubMed ID: 14999147

  • 1. Preclinical therapy of breast cancer with a radioiodinated humanized anti-EGP-1 monoclonal antibody: advantage of a residualizing iodine radiolabel.
    Govindan SV, Stein R, Qu Z, Chen S, Andrews P, Ma H, Hansen HJ, Griffiths GL, Horak ID, Goldenberg DM.
    Breast Cancer Res Treat; 2004 Mar; 84(2):173-82. PubMed ID: 14999147
    [Abstract] [Full Text] [Related]

  • 2. Advantage of a residualizing iodine radiolabel in the therapy of a colon cancer xenograft targeted with an anticarcinoembryonic antigen monoclonal antibody.
    Stein R, Govindan SV, Hayes M, Griffiths GL, Hansen HJ, Horak ID, Goldenberg DM.
    Clin Cancer Res; 2005 Apr 01; 11(7):2727-34. PubMed ID: 15814655
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Effects of radiolabeling monoclonal antibodies with a residualizing iodine radiolabel on the accretion of radioisotope in tumors.
    Stein R, Goldenberg DM, Thorpe SR, Basu A, Mattes MJ.
    Cancer Res; 1995 Jul 15; 55(14):3132-9. PubMed ID: 7606734
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Advantage of a residualizing iodine radiolabel for radioimmunotherapy of xenografts of human non-small-cell carcinoma of the lung.
    Stein R, Goldenberg DM, Thorpe SR, Mattes MJ.
    J Nucl Med; 1997 Mar 15; 38(3):391-5. PubMed ID: 9074526
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Radioimmunotherapy of head and neck cancer xenografts using 131I-labeled antibody L19-SIP for selective targeting of tumor vasculature.
    Tijink BM, Neri D, Leemans CR, Budde M, Dinkelborg LM, Stigter-van Walsum M, Zardi L, van Dongen GA.
    J Nucl Med; 2006 Jul 15; 47(7):1127-35. PubMed ID: 16818947
    [Abstract] [Full Text] [Related]

  • 11. Fractionated radioimmunotherapy of human colon carcinoma xenografts with 131I-labeled monoclonal antibody CC49.
    Buchsbaum D, Khazaeli MB, Liu T, Bright S, Richardson K, Jones M, Meredith R.
    Cancer Res; 1995 Dec 01; 55(23 Suppl):5881s-5887s. PubMed ID: 7493364
    [Abstract] [Full Text] [Related]

  • 12. Treatment of intracranial human glioma xenografts with 131I-labeled anti-tenascin monoclonal antibody 81C6.
    Lee Y, Bullard DE, Humphrey PA, Colapinto EV, Friedman HS, Zalutsky MR, Coleman RE, Bigner DD.
    Cancer Res; 1988 May 15; 48(10):2904-10. PubMed ID: 2452014
    [Abstract] [Full Text] [Related]

  • 13. Clinical-scale radiolabeling of a humanized anticarcinoembryonic antigen monoclonal antibody, hMN-14, with residualizing 131I for use in radioimmunotherapy.
    Govindan SV, Griffiths GL, Stein R, Andrews P, Sharkey RM, Hansen HJ, Horak ID, Goldenberg DM.
    J Nucl Med; 2005 Jan 15; 46(1):153-9. PubMed ID: 15632046
    [Abstract] [Full Text] [Related]

  • 14. Therapy with unlabeled and 131I-labeled pan-B-cell monoclonal antibodies in nude mice bearing Raji Burkitt's lymphoma xenografts.
    Buchsbaum DJ, Wahl RL, Normolle DP, Kaminski MS.
    Cancer Res; 1992 Dec 01; 52(23):6476-81. PubMed ID: 1423295
    [Abstract] [Full Text] [Related]

  • 15. A new radiopharmaceutical compound (131I-PR81) for radioimmunotherapy of breast cancer: labeling of antibody and its quality control.
    Mohammadnejad J, Rasaee MJ, Babaei MH, Paknejad M, Zahir MH, Salouti M, Rajabi AB, Mazidi M.
    Hum Antibodies; 2010 Dec 01; 19(4):79-88. PubMed ID: 21178279
    [Abstract] [Full Text] [Related]

  • 16. Optimization of radioimmunotherapy of renal cell carcinoma: labeling of monoclonal antibody cG250 with 131I, 90Y, 177Lu, or 186Re.
    Brouwers AH, van Eerd JE, Frielink C, Oosterwijk E, Oyen WJ, Corstens FH, Boerman OC.
    J Nucl Med; 2004 Feb 01; 45(2):327-37. PubMed ID: 14960657
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Effect of multiple, repeated doses of radioimmunotherapy on target antigen expression (breast MUC-1 mucin) in breast carcinomas.
    Peterson JA, Blank EW, Ceriani RL.
    Cancer Res; 1997 Mar 15; 57(6):1103-8. PubMed ID: 9067279
    [Abstract] [Full Text] [Related]

  • 20. Carcinoembryonic antigen as a target for radioimmunotherapy of human medullary thyroid carcinoma: antibody processing, targeting, and experimental therapy with 131I and 90Y labeled MAbs.
    Stein R, Juweid M, Mattes MJ, Goldenberg DM.
    Cancer Biother Radiopharm; 1999 Feb 15; 14(1):37-47. PubMed ID: 10850286
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.